Periodontitis Rheumatoid Arthritis Musculoskeletal Diseases 1. Periodontitis 2. Rheumatoid Arthritis
Conditions
Interventions
PHASE 1. A cross-sectional study of the prevalence of CP and its correlates in patients with RA
Tasks:
1. Assessment of prevalence of CP and its severity degrees in a population of RA patients
2. Es
Sponsors
Coimbra Rheumatology Association (ARCo)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. 18-70 years old 2. RA diagnosis according to ACR/EULAR 2010 criteria 3. Capable of understanding the study protocol and willing to provide informed consent for clinical evaluation. 4. DAS28 PCR = 3,1 (with no change in medication, dose, or formulation in RA treatment during the 3 months preceding Phase 1 periodontal evaluation and 32 weeks after) 5. Presence of at least six natural teeth 6. Moderate to Severe CP diagnosis (Clinical Attachment Level > 3mm) 7. Available for all study visits over 32 weeks
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding 2. Smoking habits (past or current) 4. Chronic respiratory disease that could lead to a present state of respiratory insufficiency 5. Presence of other conditions associated with increased CRP, namely: 5.1. Other inflammatory rheumatic diseases other than RA. 5.2. Other active inflammatory diseases (IBD, chronic infections, etc.) 5.3. Current/actual neoplastic diagnosis/treatment 6. History of infection/ antibiotic therapy within the preceding 4 weeks 7. History of periodontal therapy 6 months prior to the examination; 8. Planned hospitalization for pre-existing condition apart from RA within 32 weeks after Phase 1 periodontal evaluation 9. Hypersensitivity to chlorhexidine digluconate. 10. Contraindications to dental local anesthetic. 11. Current and past (last 6 months) participation in another intervention study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CRP levels measured using blood sample analysis at baseline, 8weeks, 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Periodontal and joint clinical parameters measured using medical evaluation at baseline, 8weeks, 24 weeks 2. Subgingival bacterial plaque: quantification of several known pathogens RT-PCR (P. gingivalis, T. forsythensis, T. denticola, P. intermedia, A.a. and F. Nucleatum) measured using laboratorial analysis (RT-PCR) of collected subgingival bacterial plaque at baseline, 8weeks, 24 weeks 3. Antibodies anti-citrullinated proteins measured using blood sample analysis at baseline, 8weeks, 24 weeks 4. Serum Cytokines (pro and anti-inflammatory) measured using blood sample analysis at baseline, 8weeks, 24 weeks | — |
Countries
Portugal
Contacts
Public ContactDaniela Silva
Outcome results
None listed